Probiotic Supplement Fails to Protect Bone Density in Postmenopausal Women
A 12-month RCT finds a lactobacilli probiotic not only failed to prevent bone loss but accelerated it slightly vs. placebo.
Summary
A rigorous double-blind trial tested whether a three-strain lactobacilli probiotic could slow the rapid bone loss that follows menopause. Over 12 months, 114 early postmenopausal women took either the probiotic or a placebo daily. Rather than protecting bone, the probiotic group showed a small but statistically significant greater decline in volumetric bone mineral density at the distal tibia compared to placebo. No benefits appeared in secondary bone measures, bone turnover markers, or inflammatory markers either. The findings challenge emerging enthusiasm for gut-bone axis interventions and suggest this particular probiotic formulation should not be recommended as a standalone strategy for preserving skeletal health in women navigating early menopause.
Detailed Summary
Bone loss accelerates sharply in the years immediately following menopause, driven by estrogen withdrawal and related shifts in calcium metabolism and immune signaling. The gut-bone axis — the idea that gut microbiome composition influences skeletal homeostasis — has attracted growing research interest as a potentially modifiable target. Probiotic supplementation has been proposed as a low-risk, accessible strategy to slow postmenopausal bone loss, but clinical evidence has been mixed and most prior trials were short or methodologically limited.
This double-blind, placebo-controlled RCT enrolled 114 women who were one to eight years postmenopausal and randomized them to either a daily multi-strain lactobacilli probiotic (Lactiplantibacillus plantarum DSM15312, DSM15313, and Lacticaseibacillus paracasei DSM13434) or placebo for 12 months. The primary endpoint was change in distal tibia total volumetric bone mineral density measured by high-resolution peripheral quantitative computed tomography (HR-pQCT), one of the most sensitive imaging tools available for bone microstructure.
The results were clearly negative and somewhat cautionary. Both groups lost bone density over the year, as expected in this population. However, the probiotic group lost significantly more at the primary site: a mean difference of -3.7 mg HA/cm³ (95% CI: -6.9 to -0.4; p = 0.027) compared to placebo. Secondary outcomes at other skeletal sites trended similarly but did not survive correction for multiple comparisons. Crucially, no differences emerged in bone turnover markers, calciotropic hormones, or inflammatory biomarkers, leaving the mechanism of any harm unclear.
For clinicians, this trial delivers an important corrective to uncritical enthusiasm around probiotics and bone health. Not all probiotic strains behave the same way, and this specific formulation appears ineffective at best and mildly detrimental at worst for bone preservation.
Caveats include the relatively modest sample size, the restriction to a single probiotic formulation, and the fact that participants were not selected based on baseline microbiome composition, which may be an important moderator of response.
Key Findings
- Probiotic group lost significantly more bone density at the distal tibia vs. placebo (-3.7 mg HA/cm³) over 12 months.
- No probiotic benefit was detected for any secondary bone density or bone turnover marker outcomes.
- Both groups experienced modest bone loss, consistent with expected early postmenopausal trajectory.
- No treatment effects on inflammatory or calciotropic biomarkers suggest the mechanism of harm remains unexplained.
- Results do not support this lactobacilli formulation as a standalone intervention for skeletal preservation.
Methodology
Double-blind, placebo-controlled RCT with 114 early postmenopausal women randomized to 12 months of daily multi-strain lactobacilli probiotic or placebo. Primary outcome was distal tibia volumetric BMD by HR-pQCT, with secondary outcomes including DXA-measured areal BMD and circulating biomarkers analyzed via linear mixed-effects models with intention-to-treat approach and multiple testing correction.
Study Limitations
The summary is based on the abstract only, as the full text is not open access. The trial tested a single specific probiotic formulation, so findings cannot be generalized to other strains or products. The modest sample size and lack of baseline microbiome characterization limit mechanistic interpretation and generalizability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.